

1 **Frequent suboptimal thermocycler ramp rate usage negatively impacts MTBDRs/**
2 **performance for second-line drug resistant tuberculosis diagnosis**

3 Brigitta Derendinger¹, Margaretha de Vos^{1,*}, Samantha Pillay¹, Rouxjeane Venter¹, John
4 Metcalfe², Yonas Ghebrekristos^{1,3}, Stephanie Minnies¹, Tania Dolby⁴, Natalie Beylis⁴, Robin
5 Warren¹, Grant Theron^{1†}

6 **Affiliations:**

7 ¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, SA-MRC Centre for
8 Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of
9 Medicine and Health Sciences, Stellenbosch University, South Africa

10 ²Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General
11 Hospital, University of California San Francisco, USA

12 ³National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa

13 ⁴National Health Laboratory Services, Green Point, Cape Town, South Africa

14 * Current affiliation: Foundation for Innovative New Diagnostics, Geneva, Switzerland

15 † **Corresponding author:** Professor Grant Theron: gtheron@sun.ac.za

16 **Short title:** Suboptimal PCR ramp rate impacts MTBDRs/

17 **Funding**

18 This work is supported by the EDCTP2 program supported by the European Union (grant
19 SF1401, OPTIMAL DIAGNOSIS), The Center for Innovation in Point-of-Care Technologies

20 for HIV/AIDS at Northwestern University (National Institute of Biomedical Imaging and
21 Bioengineering of the National Institutes of Health, Award Number U54EB027049), and the
22 National Institute of Allergy and Infectious Diseases.

23 Research reported in this publication was also supported by the South African Medical
24 Research Council. The content is the solely the responsibility of the authors and does not
25 necessarily represent the official views of the South African Medical Research Council.

26 Hain Lifesciences donated the MTBDRs⁺ kits used for the dilution series. They did not have
27 any role in study design or result interpretation.

28 **Abstract**

29 Strengthening the detection of second-line drug-resistance is a key tuberculosis (TB) control
30 priority. The performance of MTBDR_{plus}, a multidrug-resistant (MDR)-TB assay is reduced
31 when suboptimal ramp rates are used. We investigated ramp rate's effect on MTBDR_{sl}; the
32 most widely-used molecular second-line drug-resistant TB assay.

33 We tested 52 smear-negative Xpert MTB/RIF Ultra-positive sputa and a *Mycobacterium*
34 *tuberculosis* (*Mtb*) dilution series at manufacturer-recommended (2.2°C/s) or most common
35 suboptimal ramp rate (4.0°C/s; identified via an earlier survey). *Mtb*-complex DNA (TUB-
36 band)-positivity, indeterminate rates, fluoroquinolone- and second-line injectable-resistance
37 accuracy, banding differences and, separately, inter-reader variability were assessed.

38 39% of re-surveyed laboratories (5/13) did not use the manufacturer-recommended
39 MTBDR_{sl} ramp rate. On sputum, this ramp rate improved indeterminates vs. 4.0°C/s (0/52
40 vs. 7/51; p=0.006), false drug-resistance calls (0/104 vs. 6/102; p=0.013), and incorrect
41 banding calls (0/1300 vs. 55/1275; p<0.001). Valid results (neither TUB-negative,
42 indeterminate, nor any false drug-resistance calls) (52/52 vs. 41/51; p=0.001) on sputa hence
43 improved by +21% (95% CI: 8-34%) with optimal ramp rate usage. Suboptimal ramp rate
44 increased banding call inter-reader variability [52/1300 (4%) vs. 34/1300 (3%); p=0.030] on
45 sputa but not dilution series; highlighting the importance of using clinical specimens for
46 assay performance evaluations.

47 Suboptimal ramp rate contributes to poor MTBDR_{sl} performance. Ramp rate correction will
48 improve second-line drug-resistant TB diagnoses. Laboratories must ensure the optimal
49 manufacturer-recommended ramp rate is used.

50 Introduction

51 In 2019, ~10 million people fell ill with tuberculosis (TB) and ~1.3 million people died¹.
52 Drug resistant (DR)-TB is a global health problem. ~465 000 people having multidrug
53 resistant (MDR)-TB, $\geq 6\%$ of which have additional resistance to (FQs) and second line
54 injectables (SLIDs)¹. Worldwide only 52% of MDR-TB patients were tested for resistance to
55 both these drug classes and only 58% of those who start treatment successfully complete it¹.
56 Phenotypic culture-based drug susceptibility testing is slow and costly, and patients can wait
57 six months before placed on effective treatment, if at all².

58 GenoType MTBDR_{sl} (MTBDR_{sl}; Hain Lifescience, Germany)³ is one of two commercially-
59 available rapid molecular World Health Organization (WHO)-endorsed assays for the
60 detection of *Mycobacterium tuberculosis* (*Mtb*) complex and resistance to FQs and SLIDs⁴.
61 Per the WHO, MTBDR_{sl} should be done directly on sputum irrespective of smear
62 microscopy status to reduce the delay associated with culture for indirect testing⁴.

63 However, performance data for direct use on sputum are heterogenous. In a systematic
64 review and meta-analysis, smear-negative sensitivity estimates were imprecise: 80% [95%
65 confidence interval (CI) 28-99%], 80% (28-99%) and 50% (1-99%) for FQs, SLIDs and
66 XDR-TB, respectively⁵. This affected the certainty of evidence of the WHO recommendation
67 and undermined MTBDR_{sl}'s uptake.

68 MTBDR_{sl} requires thermocycling for DNA amplification. The manufacturer recommends a
69 ramp rate of $\leq 2.2^\circ\text{C}/\text{s}$, which is the speed of temperature change between PCR cycles. We
70 previously showed Genotype MTBDR_{plus} (MTBDR_{plus}; Hain Lifescience, Germany)
71 performance, which is an assay for first-line resistance, is reduced when suboptimal
72 thermocycler ramp rates are used, most so on smear-negative specimens⁶. These findings are

73 incorporated into laboratory external quality assessment programmes and WHO TB
74 laboratory training material⁷.

75 If *MTBDRsl* is also vulnerable to this phenomenon, this would result in some of the
76 thousands of people who receive this assay each day having drug resistance diagnoses
77 missed; thereby resulting in resistance to the drugs critical to protect new regimens (e.g., FQ
78 to limit bedaquiline resistance acquisition in the oral second-line regimen) remaining delayed
79 or undiagnosed^{8,9}. More broadly, this issue of ramp rate is increasingly pertinent as
80 manufacturers are designing instruments with faster thermocycling (and hence faster ramp
81 rates) to decrease time-to-result. Furthermore, many thermocyclers, especially those at entry-
82 level, do not have a customisable ramp rate.

83 We hypothesised that the heterogenous and suboptimal sensitivities reported for *MTBDRsl*
84 on smear-negative specimens were partly attributable to suboptimal ramp rate and sought to
85 generate empirical evidence of this. We assessed whether laboratories that reported use of
86 suboptimal ramp rates during our *MTBDRplus* evaluation⁶ had switched to the
87 manufacturer-recommended ramp rate, and what the observed effect had been.

88 **Methods**

89 ***Ethics statement***

90 This study was approved by the Health Research Ethics Committee of Stellenbosch
91 University (N16/04/045) and Western Cape Research Ethics Committee
92 (WC_2016RP18_637). All methods were in accordance with relevant guidelines and
93 regulations. Permission was granted to access anonymised residual specimens collected as
94 part of routine diagnostic practices and thus patient informed consent was waived.

95 ***Experimental design***

96 Ramp rate assessment was done in both an *in vitro* dilution series and clinical sputa (**Figure**
97 **1**). DNA extracted from dilution series and clinical specimens were split and compared
98 head-to-head at the manufacturer-recommended ramp rate of 2.2°C/s or the most common
99 suboptimal ramp rate of 4.0°C/s identified previously in a survey⁶. MTBDRsl was done on all
100 amplified DNA per manufacturer's instructions for use³. For sputa, programmatic MTBDRsl
101 results (done at the recommended ramp rate) were compared. All equipment is annually
102 calibrated and serviced.

103 ***MTBDRsl calls and result definitions***

104 *CC band*: This must be present for a strip to be valid as it indicates hybridisation occurred.

105 *AC band*: Present when the assay is done correctly. Per the manual¹⁰, there are rare cases
106 where the AC band disappears due to competition during the amplification reaction. In this
107 scenario, an absent AC band in combination with TUB and locus control bands is still a valid
108 result.

109 *Locus control bands (gyrA, gyrB, rrs, eis):* Need to be present for a call from that locus to not
110 be indeterminate.

111 *Positive for Mtb-complex DNA:* TUB-band present.

112 *Strip banding call:* For a band to be classified as present, it must be equal or darker than the
113 amplification control (AC) band. Overall, there are 27 possible strip bands on MTBDRsl.
114 When only the CC- and AC- bands are present, this represents a valid TUB-negative result.

115 *Diagnostic call:* Band presence or absence in a region determines whether the result is
116 classified as susceptible or resistance to a drug class (two diagnostic calls possible for
117 MTBDRsl: FQs or SLIDs).

118 *(In)determinate for a gene region and/or drug class:* For a specific gene region and/or drug
119 class to be determinate, locus control band(s) must be present. We called a strip indeterminate
120 for a drug class if at least one gene locus control was absent.

121 *Valid result:* TUB-band positive strip determinate for all gene locus controls and thus has
122 diagnostic calls for both drug classes (e.g., TUB-band positive, FQ-resistant, SLIDs-
123 susceptible).

124 ***Impact of thermocycler ramp rate on MTBDRsl performance on a dilution series***

125 A phenotypically- and genotypically-confirmed clinical XDR strain (known *gyrA*, *gyrB*, *rrs*
126 and *eis* variants) and a drug-susceptible (DS) strain (H37Rv, ATCC 25618) were grown to
127 mid-exponential phase (approximately 10^8 CFU/ml) in Middlebrook 7H9 media (Becton
128 Dickinson, United States) supplemented with Middlebrook Oleic Albumin Dextrose Catalase
129 (Becton Dickinson, United States). Serial dilutions in phosphate buffer supplemented with
130 0.025% Tween 80 (Merck, South Africa) were inoculated onto Middlebrook 7H10 solid

131 media (Becton Dickinson, United States) and incubated for 21 days at 37°C for colony
132 forming unit (CFU) calculations. This was done in biological triplicate. 1ml of the 10⁴, 10³
133 and 10²CFU/ml suspensions were GenoLysed (Hain LifeScience, Germany) and MTBDRs/
134 done per the manufacturer's instructions³. The two lower dilutions approximate to
135 smear-negative disease (<10 000CFU/ml)¹¹; expected to be most affected by suboptimal
136 ramp rate. DNA was amplified with the CFX96 thermocycler (Bio Rad Laboratories, South
137 Africa) at ramp rates of 2.2°C/s and 4.0°C/s. Two experienced readers recorded bands in a
138 blinded manner. Accuracy analyses for TUB-band positivity, indeterminate rates, incorrect
139 banding calls, and incorrect diagnostic calls were done.

140 *Impact of thermocycler ramp rate on MTBDRs/ on clinical specimens*

141 Genolysed samples (n=52) remaining after programmatic LPA testing were collected from a
142 TB laboratory in Cape Town, South Africa. These samples were, per the national algorithm,
143 derived from the paired sputum specimen of a presumptive pulmonary TB patient that
144 received Ultra (on a separate sputum), MGIT 960 culture and Auramine O microscopy (on
145 the same sputum later GenoLysed). All sputa were smear-negative and Ultra-rifampicin
146 resistant. We did not include smear-positives as we previously showed ramp rate to not affect
147 MTBDR_{plus} on smear-positives⁶. Residual GenoLysed samples were stored at -20°C.

148 Samples were categorised using programmatic LPA results as: 17 MDR-TB, 24 pre-XDR and
149 11 XDR-TB. For the experiment, DNA was amplified using a CFX96 thermocycler (Bio-
150 Rad, United States) at 2.2°C/s (manufacturer-recommended) and 4.0°C/s. MTBDRs/
151 done per the manufacturer's instructions³, and two experienced readers recorded bands in a
152 blinded fashion. Accuracy analyses for TUB-band positivity, indeterminate rates, incorrect
153 banding calls, and incorrect diagnostic calls were done.

154 *Calculation of laboratory savings from an improvement in MTBDRsl performance on*
155 *smear-negatives stemming from ramp rate*

156 We calculated how much the routine laboratory, from which we received GenoLysed
157 remnants, would save if we applied the proportional increase we found in valid results when
158 the optimal vs. the suboptimal ramp rate was used. This cost savings calculation was based
159 on the average number of MTBDRsl tests done indirectly on cultured isolates per month
160 (which would now be reduced due to direct testing on smear-negatives having improved
161 performance) and the cost of each test (including consumables, labour, and overheads; the
162 sum is pre-calculated supplied by the laboratory provider).

163 *Inter-reader agreement*

164 Three experienced readers read all strips from the dilution series and clinical specimens at
165 either ramp rate independently and in fashion blinded to each other's calls and any other
166 information regarding the specimens or strains used. Banding calls were assessed between
167 readers, as well as resultant differences in final diagnostic calls. Excluding the CC- and AC-
168 bands, and including the TUB-band, gene locus control-bands and gene-specific wildtype-
169 and mutant-bands, there are 25 possible bands per MTBDRsl strip. There are hence 450
170 possible bands total for the 18 samples in the dilution series and 1300 possible bands for the
171 52 clinical isolates. Each strip results in two diagnostic calls and there are hence 36 possible
172 diagnostic calls in total for 18 samples in the dilution series and 104 possible diagnostic calls
173 in total for the 52 clinical isolates.

174 *Follow-up survey of TB diagnostic and research laboratories*

175 We re-surveyed prior respondents (n=29) to our initial MTBDRplus-focussed survey⁶ to
176 gather information on the current MTBDRsl conditions. We also surveyed for the first-time

177 other laboratories newly-known to us to do MTBDR_s/ on smear-negative specimens (n=11).

178 Initial non-responders were re-contacted at least twice. Survey questions included whether

179 ramp rate changed and impact on non-valid results (survey in **Supplementary Material**).

180 Permission to use data in an anonymised manner was obtained.

181 *Statistical analyses*

182 Analyses was done using Stata version 15 (StataCorp) and GraphPad Prism version 8.0.1

183 (GraphPad Software) using 2-sided tests with $\alpha=0.05$. McNemar's test was used to calculate

184 differences for paired data (i.e., the same DNA tested at both ramp rates). The two-sample

185 proportion test was used for comparisons between proportions.

186 *Data availability*

187 Available from the corresponding author.

188 **Results**

189 *MTBDRsl on the dilution series at different ramp rates*

190 Overall, irrespective of ramp rate, MTBDR sl did not classify the XDR-TB strain correctly at
191 10^2 CFU/ml across all replicates. There were overall no differences between ramp rates of
192 2.2°C/s and 4.0°C/s for TUB-band detection [16/18 (89%) vs. 17/18 (94%) $p=0.547$],
193 indeterminate results [2/16 (13%) vs. 3/17 (18%); $p=0.680$], incorrect banding calls [22/400
194 (6%) vs. 33/425 (8%); $p=0.193$], or incorrect drug resistance calls [2/32 (6%) vs. 2/34 (6%);
195 $p=0.950$] (**Table 1**). Therefore, valid results did not differ significantly [14/16 (88%) vs.
196 14/17 (82%); $p=0.680$].

197 *MTBDRsl on clinical sputa at different ramp rates*

198 No TUB-band detection differences were seen at 2.2°C/s vs. 4.0 °C/s [52/52 (100%) vs.
199 51/52 (98%), $p=0.315$; one MDR-TB patient was TUB-negative only at 4.0°C/s], however,
200 indeterminate rates improved at 2.2°C/s [0/52 (0%) vs. 7/51 (14%); $p=0.006$] as did the
201 proportion of bands that appeared incorrectly [0/1300 (0%) vs. 55/1275 (4%); $p<0.001$] and
202 drug-resistance calls [0/104 (0%) vs. 6/102 (6%); $p=0.013$] (**Table 2**). The proportion of
203 patients with a valid result was hence 52/52 (100%) vs. 41/51 (80%). In other words, the
204 patients who successfully received testing for FQs and SLIDs thus improved +21% (95% CI
205 8-34%, $p<0.001$).

206 Programmatic Ultra semi-quantitative data was available for 41/52 (79%) of sputa. When
207 load in sputa that gave a valid result at 2.2°C/s was compared to samples that gave a valid
208 result at 4.0°C/s, there were no significant differences [median (IQR) C_{Tmin} 18.7 (17.7-19.9)
209 vs. 18.8 (18.0-19.9); $p=0.899$]. We had expected 2.2°C/s to result in an improved limit of

210 detection in MTBDRs l (better ability to detect higher C_{Tmin} sputa), however, we were not able
211 to detect differences.

212 *Laboratory savings*

213 If we apply the improvement in FQ and SLID testing due to optimal ramp rate usage, there
214 would be a 21% decrease in the number of tests required to be done indirectly (which would
215 require culture and a second MTBDRs l). At our local reference laboratory, ~320 MTBDRs l s
216 initially attempted on smear-negative sputum are done per month are subsequently repeated
217 on culture isolates. Hence, in a scenario where this laboratory was using an incorrect ramp
218 rate and changed to the correct rate, they would do ~67 fewer indirect MTBDRs l tests per
219 month would need to be repeated. At a total per test cost of USD 60 (6% per annum
220 inflation)¹² this translates to a saving of \$48 240 per year (only factoring in pure laboratory
221 costs).

222 *Inter-reader agreement*

223 In the dilution series, diagnostic calls did not differ between the three readers at either ramp
224 rate – all readers incorrectly classified the XDR-TB strain (as either TUB-band negative or
225 indeterminate) at all 10²CFU/ml replicates and the DS-TB strain (as indeterminate) at one of
226 the three replicates at 10²CFU/ml (**Table 3**). The proportion of disagreement between readers
227 (banding calls) did not differ at suboptimal vs. optimal ramp rates [for the DS (1/225 vs.
228 0/225; p=0.317) or XDR strain (3/225 vs. 1/225; p=0.313)].

229 In clinical sputa, however, although the disagreement in diagnostic calls did not differ
230 between readers at the optimal vs. suboptimal ramp rate [5/104 (5%) vs. 8/104 (8%);
231 p=0.390] banding calls, however, did [34/1300 (3%) vs. 52/1300 (4%); p=0.030].

232 *Additional survey*

233 Twenty-nine follow-up surveys were sent to the original respondents and 11 to new
234 laboratories. 13 total responses were received (45%), including four from new respondents
235 (**Figure 2**). 2/13 (15%) of respondents already had their ramp rate at 2.2°C/s (per their
236 response to our first survey) and 6/13 (46%) had subsequently changed their ramp rate to
237 2.2°C/s after we communicated our previous findings⁶. Concerningly, 5/13 (39%) had not
238 changed, for which varied reasons were offered (**Table 4**). Of the laboratories who changed
239 to 2.2°C/s, 4/6 (67%) reported that this resulted in an improvement in banding intensity and
240 fewer non-valid results for *MTBDRplus* and *MTBDRsl*.

241 **Discussion**

242 We evaluated for first-time thermocycler ramp rate's impact on the most widely used
243 molecular test for second-line drug-resistant TB (MTBDR_{sl}). We show: 1) in sputa valid
244 results improved by 21% when using the optimal ramp rate, which results in significant
245 laboratory cost savings and would decrease diagnostic delay, 2) banding call and drug
246 susceptibility call reader disagreement worsened at the suboptimal ramp rate, and 3) several
247 laboratory respondents had not corrected their LPA ramp rate but those that had reported
248 fewer non-valid results from MTBDR_{sl} on smear-negative specimens.

249 We had previously shown suboptimal thermocycler ramp rate negatively affects the
250 diagnostic accuracy of potentially thousands of MTBDR_{plus} assays, especially on
251 smear-negative sputa⁶, and ramp rate monitoring was incorporated in laboratory quality
252 control and training documentation⁷. Now we show that a 21% increase of MTBDR_{sl}
253 diagnoses (valid results) in smear-negative specimens is possible through ramp rate
254 correction. This is not a niche problem – we identified diagnostic laboratories who still do not
255 do MTBDR_{sl} correctly. This correction, which we have now provided MTBDR_{sl}-specific
256 empirical evidence could reduce DR-TB diagnostic care cascade gaps: a recent study found
257 that only 65% of MDR-TB cases were evaluated for FQ resistance¹³.

258 Critically, ramp rate correction will reduce repeat MTBDR_{sl} testing on isolates. Most
259 directly, this will translate into substantial laboratory cost savings in high burden countries,
260 especially when TB services are fragile due to the COVID-19 pandemic, not to mention the
261 myriad of other individual- and population-benefits that can stem from improved DST¹⁴,
262 including reduced time to treatment, transmission, and mortality.

263 Most laboratories in our follow-up survey had corrected ramp rate, however, a significant
264 amount, including those responsible for routine diagnostic testing on smear-negative
265 specimens, still used a suboptimal ramp rate. We re-iterate that 1) laboratories ensure that
266 they are using the optimal ramp rate, 2) thermocycler ramp rate monitoring be added to
267 laboratory external quality assurance programmes and accreditation processes for MTBDRs/*l*,
268 and 3) that the manufacturer makes the recommended ramp rate more prominent in assay
269 documentation. It is worth evaluating further why incorrect ramp rates continued to be used.
270 This may be due to quality assurance lapses, a deliberate choice (e.g., to potentially speed up
271 turn-around-time) without an awareness of downsides, or a design limitation of available
272 thermocyclers.

273 We saw a more prominent performance difference between ramp rates in clinical sputa than
274 in spiked solution. Bacilli in mucus sputa matrices behave differently to bacilli spiked in *in*
275 *vitro* experiments and our findings illustrates potential downsides to investigating the effect
276 of PCR parameters on molecular assays when *in vitro* or mock specimens are used.

277 Our evaluation has strengths and limitations. We did not assess a wider ramp rate range due
278 to limited sputa and cost but used the most frequently reported incorrect ramp rate. Our
279 survey results would have also been subjected to selection, response and reporting biases and
280 we suggest a formal survey is done by the manufacturer and/or the appropriate regulatory and
281 oversight agency (we did our survey independently). We did not evaluate savings stemming
282 from quicker diagnosis, treatment initiation, and long-term reductions in transmission and
283 mortality due to improved performance – there is already a saving in laboratory costs alone
284 with no downside.

285 In conclusion, we have shown that this incorrect and seemingly innocuous technical setting
286 (ramp rate) has a real-world negative impact on patients' diagnoses for second-line drug

287 resistance using MTBDR*s*/. Smear-negative patients are especially vulnerable. All
288 stakeholders must ensure that the optimal thermocycler ramp rate for MTBDR*s*/ is used, and
289 this requires investigation for other molecular diagnostics.

290 **Acknowledgments**

291 The authors thank the National Health Laboratory Services, Green Point, Cape Town, South
292 Africa, and Hain Lifescience, Germany.

293 The authors thank the laboratories that participated in the survey and provided data.

294 **Author Contributions**

295 B.D., M.dV., G.T. and R.W. conceived the experiments. T.D. and S.P. provided specimens
296 and data from the National Health Laboratory Service, Greenpoint. B.D. conducted the
297 experiments and analysed the data. S.P, Y.G., R.V. and S.M. assisted with analysis of results.
298 J.M. provided critical input. All authors reviewed the manuscript.

299 **Tables**

300 **Table 1.** MTBDR*sl* performance on a dilution series of drug susceptible- and XDR-TB
 301 strains (10^4 , 10^3 , 10^2 CFU/ml) at ramp rates of 2.2°C/s (manufacturer-recommended) or
 302 4.0°C/s (3 replicates in triplicate for each ramp rate - 18 total MTBDR*sl* results). Accuracy
 303 for TUB-band DNA and then further analysis of indeterminate rates, incorrect banding calls
 304 and incorrect diagnostic calls were done. No significant differences were seen between ramp
 305 rates using dilution series. P-values are for within-column comparisons between different
 306 ramp rates. Data are n/N (%).

Ramp rate (°C/s)	TUB-band positive	TUB-band positives			
		Indeterminate	Incorrect banding call	Incorrect diagnostic call	Valid result
2.2	16/18* (89)	2/16 [†] (13)	22/400 [‡] (6)	2/32 (6)	14/16 [†] (88)
4.0	17/18* (94) p=0.547	3/17 [†] (18) p=0.680	33/425 [§] (8) p=0.193	2/34 [¶] (6) p=0.950	14/17 [†] (82) p=0.680

307 *2 strains × 3 replicates × 3 dilutions

308 [†]TUB-positive strips

309 [‡]16 TUB-band positive strips × 25 bands per strip

310 [§]17 TUB-band positive strips × 25 bands per strip

311 ^{||}16 TUB-band positive strips × 2 drug class diagnostic calls

312 [¶]17 TUB-band positive strips × 2 diagnostic calls

313 Definitions: TUB-band positive □ positive for *Mycobacterium tuberculosis*-complex DNA; indeterminate □ one or more
 314 gene locus control is absent; incorrect banding call □ the presence or absence of a band deviating from the true banding call;
 315 incorrect diagnostic call □ the presence or absence of banding patterns resulting in deviation of the true susceptibility to a
 316 drug class; valid result □ TUB-band positive, determinate for all gene locus controls, thus having diagnostic calls for both
 317 drug classes.

318 **Table 2.** MTBDR_s performance on smear-negative sputa at ramp rates of 2.2°C/s
 319 (manufacturer-recommended) or 4.0°C/s (52 isolates). Accuracy for *Mycobacterium*
 320 *tuberculosis*-complex DNA (TUB-band), and then further analysis of indeterminate rates,
 321 incorrect banding calls and incorrect diagnostic calls were done. The number of valid results
 322 [52/52 (100%) vs. 41/51 (80%)] improved by 21% (95% CI: 8-34%; p<0.001). P-values are
 323 for within-column comparisons between different ramp rates. Data are n/N (%).

Ramp rate (°C/s)	TUB-band positive	TUB-band positives			
		Indeterminate	Incorrect banding call	Incorrect diagnostic call	Valid result
2.2	52/52* (100)	0/52† (0)	0/1300‡ (0)	0/104 (0)	52/52† (100)
4.0	51/52* (98) p=0.315	7/51† (14) p=0.006	55/1275§ (4) p<0.001	6/102 (6) p=0.013	41/51† (80) p=0.001

324 *Total number of clinical specimens

325 †TUB-positive strips

326 ‡52 TUB-band positive strips × 25 bands per strip

327 §51 TUB-band positive strips × 25 bands per strip

328 ||52 TUB-band positive strips × 2 drug class diagnostic calls

329 †51 TUB-band positive strips × 2 drug class diagnostic calls

330 Definitions: TUB-band positive □ positive for *Mycobacterium tuberculosis*-complex DNA; indeterminate □ one or more
 331 gene locus control is absent; incorrect banding call □ the presence or absence of a band deviating from the true banding call;
 332 incorrect diagnostic call □ the presence or absence of banding patterns resulting in deviation of the true susceptibility to a
 333 drug class; valid result □ TUB-band positive, determinate for all gene locus controls, thus having diagnostic calls for both
 334 drug classes

335 **Table 3.** Comparison of banding and drug susceptibility calls done on a dilution series of
 336 drug susceptible- and XDR-TB strains and clinical specimens interpreted by three
 337 experienced readers. Differences in banding calls or diagnostic calls did not differ between
 338 the three readers at either ramp rate for the dilution series of cells, neither did the drug
 339 susceptibility calls in the clinical specimens, however, significant difference between readers
 340 for banding calls on the clinical sputa occurred. P-values are for within-column comparisons
 341 between different ramp rates. Data are n/N (%).

Ramp rate (°C/s)	DS-TB strain		XDR-TB strain		Clinical specimens	
	Different banding call between readers	Different diagnostic call between readers	Different banding call between readers	Different diagnostic call between readers	Different banding call between readers	Different diagnostic call between readers
2.2	0/225* (0)	0/18† (0)	1/225* (0.4)	0/18† (0)	34/1300‡ (3)	5/104§ (5)
4.0	1/225* (0.4) p=0.317	1/18† (6) p=0.311	3/225* (1) p=0.313	0/18† (0) p>0.999	52/1300‡ (4) p=0.030	8/104§ (8) p=0.390

342 *1 strain × 3 replicates × 3 dilutions × 25 bands per strip

343 †1 strain × 3 replicates × 3 dilutions × 2 diagnostic calls

344 ‡52 clinical specimens × 25 bands per strip

345 §52 clinical specimens × 2 drug class diagnostic calls

346 Definitions: DS-TB □ drug susceptible-tuberculosis; XDR-TB □ extensively drug resistant-tuberculosis; banding call □ the
 347 presence or absence of a band deviating from the true banding call; diagnostic call □ the presence or absence of banding
 348 patterns resulting in deviation of the true susceptibility to a drug class

349 **Table 4.** Laboratories that indicated their ramp rate had not yet changed to the
350 manufacturer-recommended ramp rate of $\leq 2.2^{\circ}\text{C/s}$ since the last survey, the reason why, and
351 total number of line probe assays done per month. These laboratories do either *MTBDRplus*,
352 *MTBDRsl* or both on smear-negative specimens but data on the subtotals for each assay were
353 not collected.

Country	Reason given	Number of line probe assays done per month by this respondent laboratory
Kenya	Do not know	240
South Africa	Ramp rate change was not necessary as <i>MTBDRplus</i> assays are done on cultured isolates only and no <i>MTBDRsl</i> assays are done, as well as any changes to a standard operating procedure requires a validation process	40
Belarus	Ramp rate change in a standard operation procedure is not permitted without a prior approval process	155
Denmark	Ramp rate was not changed due to the run time of the original amplification protocol being faster	25
Spain	The thermocycler did not permit a ramp rate change	12

354

355 **Figure legends**



356 **Figure 1.** Study flow diagram for (A) *in vitro* [a dilution series of cells (10^4 , 10^3 , 10^2
357 CFU/ml)] experiment and (B) clinical experiment (sputa) to assess the impact of
358 thermocycler ramp rate on MTBDR*sl*. DNA extracted from the dilution series and clinical
359 specimens was split and MTBDR*sl* compared head-to-head at the manufacturer-recommend
360 ramp rate of 2.2°C or 4.0°C/s. TB □ tuberculosis; DS-TB □ drug susceptible tuberculosis;
361 XDR-TB □ extensively drug-resistant tuberculosis; CFU □ colony forming units; ml □
362 millilitre

363 **Figure 2.** Follow-up survey results summarising thermocycler ramp rates for MTBDR*sl*. 2/13
364 (15%) of initially surveyed laboratories already had their ramp rate set to 2.2°C/s and 5/13
365 (39%) were still using a suboptimal ramp rate of $\geq 2.2^\circ\text{C/s}$ upon resurveying. 6/13 (46%) of
366 laboratories had, since our first survey on MTBDR*plus*, changed MTBDR*sl* ramp rate to the
367 recommended ramp rate. Of these, 4/6 (67%) reported an improvement in banding intensity
368 and fewer invalid results.


369 References

- 370 1. World Health Organization. Global tuberculosis report 2020. 2020.
- 371 2. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant
372 tuberculosis. 2009; **106**(18): 7672-7.
- 373 3. Hain LifeScience. GenoType MTBDRsl VER 2.0 Instructions for Use. 2015.
- 374 4. World Health Organization. The use of molecular line probe assays for the detection of
375 resistance to second-line anti-tuberculosis drugs: policy guidance. 2016.
- 376 5. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KRJCDoSr. GenoType®
377 MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. 2016; (9).
- 378 6. Derendinger B, de Vos M, Nathavitharana RR, et al. Widespread use of incorrect PCR ramp
379 rate negatively impacts multidrug-resistant tuberculosis diagnosis (MTBDRplus). *Scientific reports*
380 2018; **8**(1): 3206.
- 381 7. World Health Organization. Drug-resistant tuberculosis: how to interpret rapid molecular
382 test results. 2020. <https://openwho.org/courses/multi-drug-resistant-tb>.
- 383 8. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis
384 treatment. 2019. <http://www.ncbi.nlm.nih.gov/books/NBK539517/> (accessed 02 April 2020).
- 385 9. Dowdy DW, Theron G, Tornheim JA, Warren R, Kendall EA. Of Testing and Treatment:
386 Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. *Clinical Infectious*
387 *Diseases* 2017: cix486.
- 388 10. Hain LifeScience. GenoType MTBDRplus VER 2.0 Instructions for Use. 2014.
389 https://www.ghdonline.org/uploads/MTBDRplusV2_0212_304A-02-02.pdf.
- 390 11. Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of
391 patients with pulmonary tuberculosis. *Antimicrobial agents and chemotherapy* 1973; **4**(2): 94-104.
- 392 12. Groessl EJ, Ganiats TG, Hillery N, et al. Cost analysis of rapid diagnostics for drug-resistant
393 tuberculosis. 2018; **18**(1): 1-10.
- 394 13. De Vos E, Scott L, Voss De Lima Y, et al. Management of rifampicin-resistant TB: programme
395 indicators and care cascade analysis in South Africa. 2021; **25**(2): 134-41.
- 396 14. Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 2019
397 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-
398 resistant and incurable tuberculosis. 2019; **7**(9): 820-6.


399



DNA from each tube in **A** and **B** were divided, and an equal aliquot used for MTBDRs/ at each ramp rate



MTBDRs/



- Suboptimal ramp rate of $\geq 2.2^\circ\text{C/s}$
- Ramp rate already set to 2.2°C/s per response to first survey
- Changed ramp rate to 2.2°C/s after communication of our previous findings
- Changed ramp rate to 2.2°C/s after communication of our previous findings (improvement in banding intensity seen and fewer invalid results)
- Changed ramp rate to 2.2°C/s after communication of our previous findings (no change seen)